Literature DB >> 9496489

Management of postoperative biliary strictures secondary to hepatic hydatid disease by endoscopic stenting.

U Yilmaz1, B Sakin, S Boyacioglu, U Saritas, T Cumhar, M Akoglu.   

Abstract

BACKGROUND/AIMS: The cases in the present study were reviewed retrospectively with the aim to demonstrate the characteristics of these strictures as well as the effectiveness of endoscopic stenting and to discuss the possible mechanisms of stricture formation.
METHODOLOGY: Thirteen cases of postoperative benign biliary strictures secondary to hepatic hydatid disease (HHD) surgery were diagnosed between 1989 and 1994. All of these cases had had surgery for HHD one or more times. Endoscopic stenting was performed in 11 of the cases. Eight cases were followed-up.
RESULTS: In 3 (29%) of the 8 cases, the stents were removed after a mean period of 35.6 months, and the patients were considered cured. These cases have been followed-up for 28 months. The remaining 5 cases have been followed-up for a mean period of 14.2 months. The overall morbidity was 18%, and there were no mortalities. The postoperative benign biliary strictures secondary to HHD were long, multiple, and located proximally. Due to these properties, surgical repair was not indicated for these cases.
CONCLUSION: Endoscopic stenting is a safe method in the treatment of postoperative benign biliary strictures secondary to hepatic hydatid disease.

Entities:  

Mesh:

Year:  1998        PMID: 9496489

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

Review 1.  Role of endoscopic retrograde cholangiopancreatography in the management of hepatic hydatid disease.

Authors:  Kemal Dolay; Sami Akbulut
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

2.  Endoscopic therapy of hepatic hydatid cyst disease in preoperative and postoperative settings.

Authors:  Bahattin Cicek; Erkan Parlak; Selcuk Disibeyaz; Dilek Oguz; Cem Cengiz; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.